Mel Evans | AP
A cheaper version of J&J’s top-selling drug, the rheumatoid arthritis treatment Remicade, could be available in the U.S. two years early after a federal judge ruled a key patent on the drug invalid.
Pfizer on Wednesday filed a lawsuit against Johnson & Johnson, saying that the drugmaker’s anticompetitive contracts with health insurers prevented biosimilar competition to its blockbuster rheumatoid arthritis drug, Remicade.
Remicade generated U.S. sales of $4.8 billion in 2016.
The case was filed in the U.S. District Court for the Eastern District of Pennsylvania.
Sell Johnson & Johnson because of its ‘stretched’ valuation: Goldman